Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET
Cerebral glucose metabolism measured with [18F]-FDG PET is a well established marker of neuronal dysfunction in neurodegeneration. The tau-protein tracer [18F]-AV-1451 PET is currently under evaluation and shows promising results. Here, we assess the feasibility of early perfusion imaging with AV-1451 as a substite for FDG PET in assessing neuronal injury.
Twenty patients with suspected neurodegeneration underwent FDG and early phase AV-1451 PET imaging. Ten one-minute timeframes were acquired after application of 200 MBq AV-1451. FDG images were acquired on a different date according to clinical protocol. Early AV-1451 timeframes were coregistered to individual FDG-scans and spatially normalized. Voxel-wise intermodal correlations were calculated on within-subject level for every possible time window. The window with highest pooled correlation was considered optimal. Z-transformed deviation maps (ZMs) were created from both FDG and early AV-1451 images, comparing against FDG images of healthy controls.
Regional patterns and extent of perfusion deficits were highly comparable to metabolic deficits. Best results were observed in a time window from 60 to 360 s (r = 0.86). Correlation strength ranged from r = 0.96 (subcortical gray matter) to 0.83 (frontal lobe) in regional analysis. ZMs of early AV-1451 and FDG images were highly similar.
Perfusion imaging with AV-1451 is a valid biomarker for assessment of neuronal dysfunction in neurodegenerative diseases. Radiation exposure and complexity of the diagnostic workup could be reduced significantly by routine acquisition of early AV-1451 images, sparing additional FDG PET.
KeywordsAv-1451 Tau-imaging Cerebral perfusion Cerebral FDG metabolism Neurodegeneration
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
IL, GNB and JH report no potential conflicts of interest. AD received consulting and speaker honoraria and research support from Siemens Healthcare, AVID Radiopharmaceuticals, Lilly, Piramal, and GE Healthcare. TvE received lecture fees from Lilly Germany, and research funding from the German Research Foundation (DFG), the Leibniz Association and the EU-joint program for neurodegenerative disease research (JPND).
- 2.Dronse J, Fliessbach K, Bischof GN, et al. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. J Alzheimers Dis. 2016:1–7.Google Scholar
- 12.Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59:4778–89.CrossRefPubMedGoogle Scholar
- 13.van Eimeren T, Bischof GN, Drzezga AE. Is tau imaging more than just ‘upside-down’ FDG imaging? J Nucl Med; Epub ahead of print 10 May 2017. https://doi.org/10.2967/jnumed.117.190082.
- 14.Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F–THK5351 uptake in the human brain. Alzheimers Res Ther; 9. Epub ahead of print 31 March 2017. https://doi.org/10.1186/s13195-017-0253-y.
- 23.Lin K-J, Hsiao I-T, Hsu J-L, et al. Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2016;43:1304–14.CrossRefPubMedGoogle Scholar
- 27.Rodriguez-Vieitez E, Leuzy A, Chiotis K, et al. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2016; 0271678X16645593 Google Scholar
- 28.Evans AC, Collins DL, Mills SR, et al. 3D statistical neuroanatomical models from 305 MRI volumes. In: Nuclear Science Symposium and Medical Imaging Conference, 1993., 1993 I.E. Conference Record. 1993, pp. 1813–1817 vol.3.Google Scholar
- 29.Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika. 1915;10:507–21.Google Scholar
- 34.Vollmar S, Čížek J, Sué M, et al. VINCI-volume imaging in neurological research, co-registration and ROIs included. In: Kremer K, Macho V, editors. Forschung und wissenschaftliches Rechnen 2003. Göttingen: GWDG; 2004. p. 115–31.Google Scholar